<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tubulointerstitial nephritis and uveitis (TINU syndrome)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tubulointerstitial nephritis and uveitis (TINU syndrome)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Tubulointerstitial nephritis and uveitis (TINU syndrome)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geoffrey Lee, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Akhtar Ashfaq, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary C Curhan, MD, ScD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 03, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>A unique subset of patients with interstitial nephritis has the tubulointerstitial nephritis and uveitis (TINU syndrome). First described in 1975 [<a href="#rid1">1</a>], more than 250 cases have now been reported [<a href="#rid2">2,3</a>]. The majority of cases have been documented in the ophthalmology and pediatric nephrology literature via case reports and small descriptive series.</p><p class="headingAnchor" id="H2"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>TINU is thought to be an immune-mediated process, the underlying mechanisms for which are not well understood [<a href="#rid4">4</a>]. Limited data suggest that modified C-reactive protein (mCRP), an autoantigen common to both the uvea and renal tubular cells, may be involved in the pathogenesis [<a href="#rid5">5</a>]. In a study of 97 patients with various kidney diseases and 40 individuals who were healthy, the prevalence of immunoglobulin G (IgG) antibodies directed against mCRP was significantly higher among patients with TINU syndrome (100 percent) compared with patients who had Sjögren-associated interstitial nephritis (29 percent), drug-induced interstitial nephritis (36 percent), glomerulonephritis (5 percent), or those who were healthy [<a href="#rid5">5</a>]. Another study by the same group confirmed that the mCRP is higher among patients with TINU syndrome and late-onset uveitis compared with those with drug-induced interstitial nephritis [<a href="#rid3">3</a>].</p><p>The inflammation in TINU syndrome is thought to be T-lymphocyte driven, based upon the histologic findings. In contrast, immune cells in patients with TINU syndrome have a paradoxical suppression of cytokine production and a decrease in peripheral immune response, as demonstrated by anergy to skin testing. This paradox is not unique to TINU, as the presence of increased tissue inflammation with concomitant suppression of peripheral immunity is also seen in patients with sarcoidosis [<a href="#rid6">6,7</a>].</p><p class="headingAnchor" id="H3"><span class="h1">RISK FACTORS AND ASSOCIATIONS</span><span class="headingEndMark"> — </span>No identifiable risk factors have been found in at least 50 percent of cases. In some instances, prior infection or the use of specific drugs (antibiotics to treat upper respiratory infections and nonsteroidal antiinflammatory drugs [NSAIDs]) has been implicated [<a href="#rid3">3,4</a>]. The Chinese herb, "goreisan," has been associated in a case report [<a href="#rid8">8</a>]. Although causality is unclear, concurrent <em>Chlamydia</em> and Epstein-Barr virus infections have been described [<a href="#rid9">9,10</a>]. TINU syndrome has also been reported in patients with autoimmune diseases like hypoparathyroidism [<a href="#rid11">11</a>], thyroid disease [<a href="#rid3">3,12</a>], immunoglobulin G4 (IgG4)-related autoimmune disease [<a href="#rid13">13</a>], rheumatoid arthritis [<a href="#rid11">11,14</a>], and thrombotic microangiopathy [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H4"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>TINU is a rare syndrome [<a href="#rid16">16,17</a>]. Most patients with TINU are adolescents and young women, with a median age of 15 years [<a href="#rid18">18</a>]. It has also been reported in older adults [<a href="#rid19">19,20</a>]. All series report a female-to-male predominance [<a href="#rid3">3,4</a>], with no particular racial affinity.</p><p>Although sporadically reported [<a href="#rid21">21-23</a>], there has been no definitive identified familial, genetic, or geographic clustering. In the past, various human leukocyte antigen (HLA) types have also been ascribed without inter-series consistency. Subsequently, however, a strong association was noted with HLA-DQA1*01, HLA-DQB1*05, and HLA-DRB1*01 in a series of 18 patients [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H5"><span class="h1">CLINICAL AND LABORATORY MANIFESTATIONS</span><span class="headingEndMark"> — </span>In addition to uveitis and interstitial nephritis, TINU may be associated with systemic findings including fever, weight loss, fatigue, malaise, anorexia, asthenia, abdominal and flank pain, arthralgias, myalgias, headache, polyuria, and/or nocturia.</p><p class="headingAnchor" id="H6"><span class="h2">Uveitis</span><span class="headingEndMark"> — </span>Patients with uveitis present with eye pain or redness; it is typically bilateral, although unilateral or alternating uveitis can be observed. This can also be accompanied by photophobia and decreased visual acuity. (See  <a class="medical medical_review" href="/z/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis"</a>.)</p><p>Since the uveitis is predominantly anterior, the majority of clinical findings include anterior chamber cells and flare, conjunctival injection, keratic precipitates, and dry eyes [<a href="#rid25">25</a>]. Posterior uveitis can also be seen, resulting in vitreous humor cells, chorioretinitis, intraretinal hemorrhages, retinal vascular sheathing, cotton wool spots, dilated retinal vessels, arteriovenous nicking, and retinal edema [<a href="#rid4">4</a>].</p><p>The uveitis has been observed to occur two months before, concurrently, and up to 14 months after the onset of the interstitial nephritis [<a href="#rid4">4</a>]. The majority of cases present after the onset of kidney disease. In a case series cited above, among 31 patients with biopsy-proven TINU syndrome, 18 patients (58 percent) developed uveitis 2 to 11 months after a diagnosis of interstitial nephritis was made by kidney biopsy [<a href="#rid3">3</a>].</p><p>In approximately 20 percent of patients with uveitis, intraocular complications have been noted. These include posterior synechiae, optic disc swelling, cystoid macular edema, chorioretinal scar formation, cataracts, and glaucoma.</p><p class="headingAnchor" id="H7"><span class="h2">Kidney manifestations</span><span class="headingEndMark"> — </span>Kidney manifestations with TINU syndrome are typical for acute interstitial nephritis. These may include flank pain, sterile pyuria, hematuria, proteinuria (usually subnephrotic range), kidney function impairment, and acute kidney injury (AKI) (see  <a class="medical medical_review" href="/z/d/html/7196.html" rel="external">"Urinalysis in the diagnosis of kidney disease"</a>). Multiple proximal and distal tubular defects can be commonly seen, resulting in aminoaciduria, glucosuria, phosphaturia, and acidification defects [<a href="#rid26">26-28</a>] (see  <a class="medical medical_review" href="/z/d/html/2327.html" rel="external">"Overview and pathophysiology of renal tubular acidosis and the effect on potassium balance"</a>). Kidney sonography can demonstrate marked swelling of the kidneys.</p><p class="headingAnchor" id="H8"><span class="h2">Laboratory findings</span><span class="headingEndMark"> — </span>There are no specific serum markers or laboratory findings that are unique to patients with TINU. Laboratory findings may include leukocyturia, eosinophilia, anemia, slightly abnormal liver function tests, and an elevated erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) [<a href="#rid3">3</a>]. Glycosuria may be observed [<a href="#rid3">3</a>]. Associations of TINU with a variety of serologic markers in the absence of their correspondent disease have been reported. Thus, the disorder has been associated with antineutrophil cytoplasmic antibody (ANCA) [<a href="#rid29">29</a>]; antinuclear antibody (ANA), an autoantibody directed against renal tubular cells [<a href="#rid30">30</a>]; rheumatoid factor (RF); and hypocomplementemia [<a href="#rid31">31</a>]. In addition, antibodies that react to both tubular and uveal cells have been identified in the serum of a patient with TINU syndrome [<a href="#rid2">2</a>].</p><p>Elevations have been found in serum levels of beta-2 microglobulin and Krebs Von Den Lunge-6 (KL-6), a glycoprotein found in lung tissue of normal individuals as well as in the distal renal tubules of patients with TINU syndrome [<a href="#rid32">32</a>]. However, in a larger study by the same group, serum and kidney KL-6 levels were not different between patients with TINU syndrome and drug-induced interstitial nephritis [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H9"><span class="h1">DIAGNOSIS AND HISTOLOGIC FINDINGS</span><span class="headingEndMark"> — </span>The definitive diagnosis of TINU syndrome is nonspecific and is suggested by the combination of uveitis and kidney involvement, with kidney biopsy consistent with acute interstitial nephritis. On light microscopy, typical biopsy findings include tubulointerstitial edema and infiltration of inflammatory cells composed mainly of mononuclear cells, such as lymphocytes, plasma cells, and histiocytes. Eosinophils and noncaseating granulomas are frequently seen, with neutrophils also being observed [<a href="#rid33">33</a>]. Glomerular and vascular structures are generally preserved. Findings with immunofluorescence and electron microscopy are also nonspecific.</p><p>Patients who are determined to have acute interstitial nephritis on kidney biopsy and have no obvious, underlying cause may require a slit lamp examination to exclude uveitis and TINU syndrome. However, many patients with TINU syndrome present with late-onset uveitis, and, thus, the initial slit lamp examination will be negative (see <a class="local">'Uveitis'</a> above). Such patients who are suspected as having TINU but have a negative slit lamp examination should be followed for at least 12 months for the emergence of signs and symptoms of uveitis.</p><p>Bone marrow and lymph node granulomas can be present as well, representing the systemic nature of the disease.</p><p class="headingAnchor" id="H10"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The differential diagnosis for interstitial nephritis occurring in association with ocular findings is broad. Thus, the following disorders should be considered in this setting:</p><p class="bulletIndent1"><span class="glyph">●</span>Sarcoidosis</p><p class="bulletIndent1"><span class="glyph">●</span>Sjögren's disease</p><p class="bulletIndent1"><span class="glyph">●</span>Systemic lupus erythematosus</p><p class="bulletIndent1"><span class="glyph">●</span>Granulomatosis with polyangiitis</p><p class="bulletIndent1"><span class="glyph">●</span>Behçet syndrome</p><p class="bulletIndent1"><span class="glyph">●</span>Infectious diseases, such as tuberculosis, brucellosis, toxoplasmosis, and histoplasmosis</p><p></p><p>Many of these disorders may present with additional ocular findings that are distinct from uveitis, as well as evidence of other organ involvement, thereby helping suggest the correct diagnosis.</p><p>However, sarcoidosis and Sjögren's disease share similar findings with TINU, making accurate diagnosis difficult in the absence of characteristic involvement of other organs. (See  <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">"Kidney disease in primary Sjögren's disease"</a> and  <a class="medical medical_review" href="/z/d/html/7186.html" rel="external">"Kidney disease in sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/4353.html" rel="external">"Clinical manifestations and diagnosis of sarcoidosis"</a> and  <a class="medical medical_review" href="/z/d/html/5603.html" rel="external">"Diagnosis and classification of Sjögren’s disease"</a>.)</p><p>It may be difficult to distinguish patients with TINU syndrome and late-onset uveitis from those with drug-induced interstitial nephritis (see <a class="local">'Uveitis'</a> above). A high modified C-reactive protein (mCRP) may help to identify such patients. In the study cited above, among 18 patients with TINU syndrome and late-onset uveitis, compared with 61 patients with drug-induced interstitial nephritis, a high mCRP at the time of kidney biopsy was an independent risk factor for the development of uveitis [<a href="#rid3">3</a>]. In this study, a mCRP of 20.2 percent predicted uveitis with a sensitivity and specificity of 64 and 88 percent, respectively.</p><p class="headingAnchor" id="H11"><span class="h1">MANAGEMENT AND PROGNOSIS</span></p><p class="headingAnchor" id="H12"><span class="h2">Kidney disease</span><span class="headingEndMark"> — </span>Kidney disease in patients with TINU is generally believed to be self-limited [<a href="#rid34">34</a>]. In a series of 10 patients, 8 of whom had creatinine clearances of &lt;70 mL/min/1.73 m<sup>2</sup>, kidney function returned to normal levels within one year in all patients [<a href="#rid34">34</a>]. Although seven were administered systemic steroids for uveitis, kidney function recovery was independent of such therapy or the relapse of eye disease.</p><p>However, in another series including 25 patients with TINU syndrome, 80 percent had an estimated glomerular filtration rate (eGFR) &lt;60 mL/min/1.73 m<sup>2</sup> by one year [<a href="#rid3">3</a>]. It is not clear why patients described in this report had such poor outcomes.</p><p>Patients with progressive kidney function impairment are typically treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 1 mg/kg per day (typically between 40 to 60 mg/day). Therapy is given for three to six months (with the duration of therapy dependent upon the response) and then slowly tapered. Most patients recover normal kidney function. This regimen is similar to (but more prolonged than) therapy in acute interstitial nephritis. However, relapses are more likely to occur in TINU syndrome because of the potential immunologic basis of the disease and the lack of a possible culprit agent. (See  <a class="medical medical_review" href="/z/d/html/7233.html" rel="external">"Treatment of acute interstitial nephritis"</a>.)</p><p><a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">Mycophenolate</a> mofetil has been used in a limited number of patients with acute interstitial nephritis and in one reported patient with TINU for the treatment of progressive kidney function impairment [<a href="#rid35">35,36</a>]. (See  <a class="medical medical_review" href="/z/d/html/7233.html" rel="external">"Treatment of acute interstitial nephritis"</a>.)</p><p>The prognosis appears to be dependent upon multiple variables. Some studies have suggested that the degree of tubulointerstitial fibrosis determines prognosis [<a href="#rid37">37</a>]. However, another study suggested that chronicity on biopsy was not correlated with prognosis [<a href="#rid3">3</a>]. In this study of 25 patients, the eGFR at 12 months correlated with age (r = 0.54), presence of thyroid disease (r = 0.44), erythrocyte sedimentation rate (ESR; r = 0.47), leukocyturia (r = 0.45), and serum creatinine at the time of biopsy (r = 0.44). However, no clinical, laboratory, or histologic factors were able to predict a poor outcome. Other data suggest that the prognosis is less favorable in children with TINU [<a href="#rid38">38,39</a>].</p><p>Although a few patients with TINU have required kidney replacement therapy, even these patients can expect to only temporarily require dialysis [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H13"><span class="h2">Uveitis</span><span class="headingEndMark"> — </span>Topical and systemic corticosteroids have been used for uveitis with success. However, recurrences and relapses of uveitis are common; infrequently, steroid-sparing immunosuppressive agents such as <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, and <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil are needed. The optimal management of the patient with uveitis requires early referral to and management by an ophthalmologist. (See  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a>.)</p><p class="headingAnchor" id="H3910948217"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/110749.html" rel="external">"Society guideline links: Chronic kidney disease in adults"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> – TINU syndrome is defined by the combination of tubulointerstitial nephritis and uveitis. First described in 1975, most cases have been documented via case reports and small descriptive series. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – The pathogenesis of TINU syndrome is unknown. Limited evidence suggests that an autoantigen to modified C-reactive protein (mCRP) may underlie the pathogenesis of the disease. Delayed-type hypersensitivity and suppressed cell-mediated immunity, with a predominance of T lymphocytes, likely also play a significant role. Proliferation and activation of T lymphocytes by interleukin-2 (IL-2) have been implicated. (See <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Most patients with TINU are adolescents and young women, although it has been reported in adults and older adults. There is a female-to-male predominance, with no particular racial affinity. Reported risk factors and associations include (see <a class="local">'Epidemiology'</a> above and <a class="local">'Risk factors and associations'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>HLA-DQA1*01, HLA-DQB1*05, and HLA-DRB1*01</p><p class="bulletIndent2"><span class="glyph">•</span>Prior infection or the use of specific drugs (antibiotics and nonsteroidal antiinflammatory drugs [NSAIDs]) </p><p class="bulletIndent2"><span class="glyph">•</span>The Chinese herb "goreisan"</p><p class="bulletIndent2"><span class="glyph">•</span>Concurrent <em>Chlamydia</em> and Epstein-Barr virus infection </p><p class="bulletIndent2"><span class="glyph">•</span>Autoimmune diseases like hypoparathyroidism, thyroid disease, immunoglobulin G4 (IgG4)-related autoimmune disease, and rheumatoid arthritis. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical and laboratory manifestations</strong> – TINU may be associated with systemic findings including fever, weight loss, fatigue, malaise, anorexia, asthenia, abdominal and flank pain, arthralgias, myalgias, headache, polyuria, and/or nocturia. (See <a class="local">'Clinical and laboratory manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Renal manifestations include flank pain, sterile pyuria, hematuria, proteinuria (usually subnephrotic range), kidney function impairment, and acute kidney injury (AKI). Proximal and distal tubular defects can be seen, resulting in aminoaciduria, glucosuria, phosphaturia, and acidification defects. Kidney sonography may demonstrate marked swelling of the kidneys. (See <a class="local">'Kidney manifestations'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with uveitis usually present with bilateral eye pain or redness accompanied by photophobia and decreased visual acuity, usually after the onset of kidney disease. (See <a class="local">'Uveitis'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Laboratory findings include eosinophilia, anemia, slightly abnormal liver function tests, and an elevated erythrocyte sedimentation rate (ESR). TINU syndrome has been associated with antineutrophil cytoplasmic antibody (ANCA); antinuclear antibody (ANA), an autoantibody directed against renal tubular cells; rheumatoid factor (RF); and hypocomplementemia. (See <a class="local">'Laboratory findings'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of TINU syndrome is suggested by the combination of uveitis and kidney involvement, with kidney biopsy consistent with acute interstitial nephritis. The differential diagnosis includes sarcoidosis, Sjögren's disease, systemic lupus erythematosus, granulomatosis with polyangiitis, Behçet syndrome, and infectious diseases such as tuberculosis, brucellosis, toxoplasmosis, and histoplasmosis. The distinction of TINU syndrome from sarcoidosis and Sjögren's disease is particularly difficult. (See <a class="local">'Diagnosis and histologic findings'</a> above and <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management and prognosis</strong> – Kidney disease in patients with TINU is usually variable. Patients with progressive kidney function impairment are typically treated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at a dose of 1 mg/kg per day (typically between 40 to 60 mg/day) for three to six months (with the duration of therapy dependent upon the response) and then slowly tapered. The optimal management of the patient with uveitis requires early referral to and management by an ophthalmologist. (See <a class="local">'Management and prognosis'</a> above and <a class="local">'Uveitis'</a> above and  <a class="medical medical_review" href="/z/d/html/5592.html" rel="external">"Uveitis: Treatment"</a>.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dobrin RS, Vernier RL, Fish AL. Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome. Am J Med 1975; 59:325.</a></li><li><a class="nounderline abstract_t">Abed L, Merouani A, Haddad E, et al. Presence of autoantibodies against tubular and uveal cells in a patient with tubulointerstitial nephritis and uveitis (TINU) syndrome. Nephrol Dial Transplant 2008; 23:1452.</a></li><li><a class="nounderline abstract_t">Li C, Su T, Chu R, et al. Tubulointerstitial nephritis with uveitis in Chinese adults. Clin J Am Soc Nephrol 2014; 9:21.</a></li><li><a class="nounderline abstract_t">Mandeville JT, Levinson RD, Holland GN. The tubulointerstitial nephritis and uveitis syndrome. Surv Ophthalmol 2001; 46:195.</a></li><li><a class="nounderline abstract_t">Tan Y, Yu F, Qu Z, et al. Modified C-reactive protein might be a target autoantigen of TINU syndrome. Clin J Am Soc Nephrol 2011; 6:93.</a></li><li><a class="nounderline abstract_t">Gafter U, Kalechman Y, Zevin D, et al. Tubulointerstitial nephritis and uveitis: association with suppressed cellular immunity. Nephrol Dial Transplant 1993; 8:821.</a></li><li><a class="nounderline abstract_t">Yoshioka K, Takemura T, Kanasaki M, et al. Acute interstitial nephritis and uveitis syndrome: activated immune cell infiltration in the kidney. Pediatr Nephrol 1991; 5:232.</a></li><li><a class="nounderline abstract_t">Suzuki H, Yoshioka K, Miyano M, et al. Tubulointerstitial nephritis and uveitis (TINU) syndrome caused by the Chinese herb "Goreisan". Clin Exp Nephrol 2009; 13:73.</a></li><li><a class="nounderline abstract_t">Stupp R, Mihatsch MJ, Matter L, Streuli RA. Acute tubulo-interstitial nephritis with uveitis (TINU syndrome) in a patient with serologic evidence for Chlamydia infection. Klin Wochenschr 1990; 68:971.</a></li><li><a class="nounderline abstract_t">Grefer J, Santer R, Ankermann T, et al. Tubulointerstitial nephritis and uveitis in association with Epstein-Barr virus infection. Pediatr Nephrol 1999; 13:336.</a></li><li><a class="nounderline abstract_t">Catalano C, Harris PE, Enia G, et al. Acute interstitial nephritis associated with uveitis and primary hypoparathyroidism. Am J Kidney Dis 1989; 14:317.</a></li><li><a class="nounderline abstract_t">Paul E, Van Why S, Carpenter TO. Hyperthyroidism: a novel feature of the tubulointerstitial nephritis and uveitis syndrome. Pediatrics 1999; 104:314.</a></li><li><a class="nounderline abstract_t">Yoneda K, Murata K, Katayama K, et al. Tubulointerstitial nephritis associated with IgG4-related autoimmune disease. Am J Kidney Dis 2007; 50:455.</a></li><li><a class="nounderline abstract_t">Iida H, Terada Y, Nishino A, et al. Acute interstitial nephritis with bone marrow granulomas and uveitis. Nephron 1985; 40:108.</a></li><li><a class="nounderline abstract_t">Zhao Y, Huang J, Su T, et al. Acute Kidney Injury Relevant to Tubulointerstitial Nephritis with Late-Onset Uveitis Superimposed by Thrombotic Microangiopathy: A Case Report and Review of the Literature. Kidney Dis (Basel) 2020; 6:414.</a></li><li><a class="nounderline abstract_t">Mackensen F, Smith JR, Rosenbaum JT. Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome. Ophthalmology 2007; 114:995.</a></li><li><a class="nounderline abstract_t">Okafor LO, Hewins P, Murray PI, Denniston AK. Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors. Orphanet J Rare Dis 2017; 12:128.</a></li><li><a class="nounderline abstract_t">Sessa A, Meroni M, Battini G, et al. Acute renal failure due to idiopathic tubulo-intestinal nephritis and uveitis: "TINU syndrome". Case report and review of the literature. J Nephrol 2000; 13:377.</a></li><li><a class="nounderline abstract_t">Cacoub P, Deray G, Le Hoang P, et al. Idiopathic acute interstitial nephritis associated with anterior uveitis in adults. Clin Nephrol 1989; 31:307.</a></li><li><a class="nounderline abstract_t">Salu P, Stempels N, Vanden Houte K, Verbeelen D. Acute tubulointerstitial nephritis and uveitis syndrome in the elderly. Br J Ophthalmol 1990; 74:53.</a></li><li><a class="nounderline abstract_t">Gianviti A, Greco M, Barsotti P, Rizzoni G. Acute tubulointerstitial nephritis occurring with 1-year lapse in identical twins. Pediatr Nephrol 1994; 8:427.</a></li><li><a class="nounderline abstract_t">Howarth L, Gilbert RD, Bass P, Deshpande PV. Tubulointerstitial nephritis and uveitis in monozygotic twin boys. Pediatr Nephrol 2004; 19:917.</a></li><li><a class="nounderline abstract_t">Dusek J, Urbanova I, Stejskal J, et al. Tubulointerstitial nephritis and uveitis syndrome in a mother and her son. Pediatr Nephrol 2008; 23:2091.</a></li><li><a class="nounderline abstract_t">Levinson RD, Park MS, Rikkers SM, et al. Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome. Invest Ophthalmol Vis Sci 2003; 44:653.</a></li><li><a class="nounderline abstract_t">Rosenbaum JT. Bilateral anterior uveitis and interstitial nephritis. Am J Ophthalmol 1988; 105:534.</a></li><li><a class="nounderline abstract_t">Igarashi T, Kawato H, Kamoshita S, et al. Acute tubulointerstitial nephritis with uveitis syndrome presenting as multiple tubular dysfunction including Fanconi's syndrome. Pediatr Nephrol 1992; 6:547.</a></li><li><a class="nounderline abstract_t">Koike K, Lida S, Usui M, et al. Adult-onset acute tubulointerstitial nephritis and uveitis with Fanconi syndrome. Case report and review of the literature. Clin Nephrol 2007; 67:255.</a></li><li><a class="nounderline abstract_t">Vô B, Yombi JC, Aydin S, et al. TINU-associated Fanconi syndrome: a case report and review of literature. BMC Nephrol 2018; 19:274.</a></li><li><a class="nounderline abstract_t">Simon AH, Alves-Filho G, Ribeiro-Alves MA. Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody. Am J Kidney Dis 1996; 28:124.</a></li><li><a class="nounderline abstract_t">Wakaki H, Sakamoto H, Awazu M. Tubulointerstitial nephritis and uveitis syndrome with autoantibody directed to renal tubular cells. Pediatrics 2001; 107:1443.</a></li><li><a class="nounderline abstract_t">Conz PA, Milan M, Bragantini L, et al. TINU syndrome associated with reduced complement levels. Nephron 2001; 89:340.</a></li><li><a class="nounderline abstract_t">Kase S, Kitaichi N, Namba K, et al. Elevation of serum Krebs von den Lunge-6 levels in patients with tubulointerstitial nephritis and uveitis syndrome. Am J Kidney Dis 2006; 48:935.</a></li><li><a class="nounderline abstract_t">Joss N, Morris S, Young B, Geddes C. Granulomatous interstitial nephritis. Clin J Am Soc Nephrol 2007; 2:222.</a></li><li><a class="nounderline abstract_t">Takemura T, Okada M, Hino S, et al. Course and outcome of tubulointerstitial nephritis and uveitis syndrome. Am J Kidney Dis 1999; 34:1016.</a></li><li><a class="nounderline abstract_t">Neilson EG, Farris AB. Case records of the Massachusetts General Hospital. Case 21-2009. A 61-year-old woman with abdominal pain, weight loss, and renal failure. N Engl J Med 2009; 361:179.</a></li><li><a class="nounderline abstract_t">Preddie DC, Markowitz GS, Radhakrishnan J, et al. Mycophenolate mofetil for the treatment of interstitial nephritis. Clin J Am Soc Nephrol 2006; 1:718.</a></li><li><a class="nounderline abstract_t">van Leusen R, Assmann KJ. Acute tubulo-interstitial nephritis with uveitis and favourable outcome after five months of continuous ambulatory peritoneal dialysis (CAPD). Neth J Med 1988; 33:133.</a></li><li><a class="nounderline abstract_t">Rytkönen S, Tainio J, Saarela V, et al. Long-term outcome of biopsy-proven idiopathic tubulointersitial nephritis with or without uveitis in children-a nationwide follow-up study. Pediatr Nephrol 2021; 36:3663.</a></li><li><a class="nounderline abstract_t">Chevalier A, Duflos C, Clave S, et al. Renal Prognosis in Children With Tubulointerstitial Nephritis and Uveitis Syndrome. Kidney Int Rep 2021; 6:3045.</a></li></ol></div><div id="topicVersionRevision">Topic 7189 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1163543" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Acute eosinophilic interstitial nephritis and renal failure with bone marrow-lymph node granulomas and anterior uveitis. A new syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18156461" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Presence of autoantibodies against tubular and uveal cells in a patient with tubulointerstitial nephritis and uveitis (TINU) syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24202135" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Tubulointerstitial nephritis with uveitis in Chinese adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11738428" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The tubulointerstitial nephritis and uveitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20813859" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Modified C-reactive protein might be a target autoantigen of TINU syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8255514" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Tubulointerstitial nephritis and uveitis: association with suppressed cellular immunity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2031842" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Acute interstitial nephritis and uveitis syndrome: activated immune cell infiltration in the kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18661195" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Tubulointerstitial nephritis and uveitis (TINU) syndrome caused by the Chinese herb "Goreisan".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2232628" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Acute tubulo-interstitial nephritis with uveitis (TINU syndrome) in a patient with serologic evidence for Chlamydia infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10454786" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Tubulointerstitial nephritis and uveitis in association with Epstein-Barr virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2801703" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Acute interstitial nephritis associated with uveitis and primary hypoparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10429017" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hyperthyroidism: a novel feature of the tubulointerstitial nephritis and uveitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17720525" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tubulointerstitial nephritis associated with IgG4-related autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4000329" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Acute interstitial nephritis with bone marrow granulomas and uveitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33313062" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Acute Kidney Injury Relevant to Tubulointerstitial Nephritis with Late-Onset Uveitis Superimposed by Thrombotic Microangiopathy: A Case Report and Review of the Literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17383731" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Enhanced recognition, treatment, and prognosis of tubulointerstitial nephritis and uveitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28709457" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Tubulointerstitial nephritis and uveitis (TINU) syndrome: a systematic review of its epidemiology, demographics and risk factors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063143" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Acute renal failure due to idiopathic tubulo-intestinal nephritis and uveitis: "TINU syndrome". Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2665992" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Idiopathic acute interstitial nephritis associated with anterior uveitis in adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2407289" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Acute tubulointerstitial nephritis and uveitis syndrome in the elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7947032" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Acute tubulointerstitial nephritis occurring with 1-year lapse in identical twins.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15206033" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Tubulointerstitial nephritis and uveitis in monozygotic twin boys.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18528711" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tubulointerstitial nephritis and uveitis syndrome in a mother and her son.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12556395" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Strong associations between specific HLA-DQ and HLA-DR alleles and the tubulointerstitial nephritis and uveitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3369519" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Bilateral anterior uveitis and interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1482643" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Acute tubulointerstitial nephritis with uveitis syndrome presenting as multiple tubular dysfunction including Fanconi's syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17474563" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Adult-onset acute tubulointerstitial nephritis and uveitis with Fanconi syndrome. Case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30340545" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : TINU-associated Fanconi syndrome: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8712206" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Acute tubulointerstitial nephritis and uveitis with antineutrophil cytoplasmic antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11389273" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Tubulointerstitial nephritis and uveitis syndrome with autoantibody directed to renal tubular cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11598400" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : TINU syndrome associated with reduced complement levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17162148" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Elevation of serum Krebs von den Lunge-6 levels in patients with tubulointerstitial nephritis and uveitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699417" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Granulomatous interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10585310" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Course and outcome of tubulointerstitial nephritis and uveitis syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19587344" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Case records of the Massachusetts General Hospital. Case 21-2009. A 61-year-old woman with abdominal pain, weight loss, and renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699278" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Mycophenolate mofetil for the treatment of interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3226446" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Acute tubulo-interstitial nephritis with uveitis and favourable outcome after five months of continuous ambulatory peritoneal dialysis (CAPD).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34008125" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Long-term outcome of biopsy-proven idiopathic tubulointersitial nephritis with or without uveitis in children-a nationwide follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34901573" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Renal Prognosis in Children With Tubulointerstitial Nephritis and Uveitis Syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
